Table 2.
Oral HPV DNA Prevalence in Patients With HPV-OPC and Their Partners Compared With General US Population of Similar Age (NHANES)
| NHANES Population (%)* | Partners |
Patients |
|||
|---|---|---|---|---|---|
| No. | % | No. | % | ||
| Baseline | (n = 93) | (n = 164) | |||
| Any oral HPV | 9.1 | 4† | 4.3 | 106 | 64.6 |
| Any oncogenic HPV | 4.7 | 1† | 1.1 | 100‡ | 61.0 |
| HPV16 | 1.4 | 0 | 0.0 | 88 | 53.7 |
| HPV16 qPCR ≥ 3§ | — | 0 | 0.0 | 71 | 45.5 |
| HPV16 qPCR > 0§ | — | 2 | 2.3 | 83 | 53.2 |
| Among women | (n = 87) | (n = 17) | |||
| Any oral HPV at baseline | 4.3 | 2 | 2.3 | 11 | 64.7 |
| Any oncogenic HPV | 1.3 | 1 | 1.2 | 10 | 58.8 |
| HPV16 at baseline | 0.5 | 0 | 0.0 | 9 | 52.9 |
| Among men | (n = 6) | (n = 147) | |||
| Any oral HPV at baseline | 14.0 | 2 | 33.3 | 95 | 64.3 |
| Any oncogenic HPV | 8.2 | 0 | 0.0 | 90 | 61.2 |
| HPV16 at baseline | 2.4 | 0 | 0.0 | 79 | 53.7 |
Abbreviations: HPV, human papillomavirus; HPV-OPC, human papillomavirus– positive oropharyngeal cancer; NHANES, National Health and Nutrition Examination Survey; qPCR, quantitative polymerase chain reaction.
Ages 45 to 65 years.
Oral HPV infection detected among partners included one infection with HPV51 (oncogenic), one infection with HPV83 (nononcogenic), two infections with HPV62 (nononcogenic), and two HPV16 infections detected by qPCR only.
Majority of oncogenic oral HPV infections detected in oral rinse samples of patients with HPV-OPC were HPV16 (88 of 100; 88%). Other oncogenic oral HPV infections detected included: 14 HPV52 infections (8.5%), four HPV33 infections (2.4%), three HPV73 infections (1.8%), two infections each for HPV59 and HPV51 (1.2%), and one infection each for HPV18, 39, 45, and 56 (0.6%).
All oral HPV results presented, including HPV16 results, were generated by line blot unless specifically indicated by qPCR.